Recent studies have reported that statin use may be associated with improved outcomes in patients with sepsis or respiratory viral infections. In the setting of allogeneic hematopoietic cell transplantation (HCT), it has been shown that donor and recipient statin use is associated with reduced risks of GVHD. We assessed in retrospective analysis whether donor or recipient statin use impacts infection risk after allogeneic HCT (n = 1191). Although recipient statin use was associated with the increased incidence of Gramnegative bacteremia (adjusted hazard ratio (aHR) 2.22, (95% confidence interval (CI) 1.2-4.2), P = 0.01) without affecting mortality, donor statin use was associated with an increased incidence of respiratory viral infections in recipients (aHR 2.84 (95% CI 1.3-6.0), P = 0.007). The overall incidence of invasive fungal infections and CMV reactivation and CMV disease were not impacted by recipient or donor statin use. In conclusion, this study suggests that recipient or donor statin use may be associated with an increased incidence of some infections without adversely affecting mortality.
INTRODUCTION
Statins reduce cholesterol levels through inhibition of HMG-CoA reductase but they also have anti-inflammatory and immunomodulatory properties. [1] [2] [3] [4] Although the results are conflicting, several studies have suggested that statin use is associated with reduced incidence of infections or infection-related mortality. [5] [6] [7] [8] [9] [10] [11] [12] [13] We previously reported that recipient or donor statin use was associated with a reduced risk of GVHD, 14, 15 and a recent phase II study also suggested GVHD-protective effects. 16 Although infections after hematopoietic cell transplantation (HCT) are known to correlate with GVHD, [17] [18] [19] [20] data on the potential impact of statin use on infection risk or outcome in the HCT setting are limited. 21 Thus, the objective of this study was to evaluate the effects of donor or recipient statin use on infections after allogeneic HCT.
PATIENTS AND METHODS

Study design
We retrospectively analyzed a previously reported cohort of HCT recipients for infection incidence and outcomes. 14 The Institutional Review Board at Fred Hutchinson Cancer Research Center (FHCRC) had approved this study. The cohort included 1191 allogeneic HCT recipients transplanted from HLA-identical sibling or HLA-matched unrelated donors between 2001 and 2008. To increase the likelihood of statin treatment for hyperlipidemia, recipients and donors had to be at least 18 and 30 years of age, respectively, to be eligible for the study. Information on incident infections and infection-related outcomes was retrieved from medical records and the FHCRC research database.
Definitions
'Statin-treatment' of recipients was defined as treatment of hyperlipidemia with any statin at any dose for at least 3 consecutive months before HCT and during any time after HCT.
14 Donors were considered 'statin-treated' when they had been treated with a statin at the time of stem cell donation for at least 3 months. The usual indication for statin treatment was hyperlipidemia.
Myeloablative conditioning regimens consisted mainly of high-dose CY and BU or fractionated TBI (⩾12 Gy). Reduced intensity conditioning regimens consisted of a single fraction of TBI (2-3 Gy) with or without fludarabine. The degree of mucositis after HCT was scored using the oral mucositis index. 22 Only the first event of each infection was analyzed. Bacteremia and candidemia were diagnosed by positive blood culture. Coagulase-negative staphylococci were excluded from significant pathogens of bacteremia. Probable and proven cases of mold infections were identified according to definitions of the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG). 23 Patients were monitored for CMV reactivation by weekly CMV pp65 antigenemia testing. CMV disease was diagnosed based on standardized criteria. 24 Respiratory viral infection was defined as the detection of a respiratory virus in the respiratory tract. Lower respiratory tract viral disease (LRD) was defined as the viral detection in a sample of bronchoalveolar lavage or lung biopsy with lower respiratory tract symptoms and/or abnormal radiographic findings. 25 
Statistical analysis
Patient characteristics were compared according to patient or donor statin use with the χ 2 -test for categorical variables and the Wilcoxon rank sum test for continuous variables. Multivariate associations between incidence of each infection and statin use were evaluated using Cox proportional hazards models, treating death without infection as a competing risk. Cox regression models were also used to evaluate the association between statin use and mortality due to infection within the first 30 days after infection. Cumulative incidence of infection was estimated using standard methods, treating death without infection as a competing risk. All P-values are two sided and are not adjusted for multiple comparisons.
RESULTS
Patient characteristics
Among 1191 HCT recipients transplanted from related (n = 603) or unrelated (n = 588) donors, 76 (6.4%) were statin treated. Information regarding donor statin treatment was available for 557 transplant recipients (91%) who had sibling donors. Among those, 85 recipients (15%) had statin-treated donors. Patient characteristics are shown in Table 1 . The median age at HCT was significantly higher among statin-treated recipients compared with recipients not treated with a statin (60 (range, 31-72) vs 52 (range, 20-79) years old, P o 0.0001). Reduced intensity conditioning was more common among statin-treated recipients (59% vs 39%, P = 0.0007).
Incidence of infections by recipient statin use The incidence of each infection by recipient statin use and results of univariate and multivariate analyses are shown in Table 2 . The probability of Gram-negative bacteremia was higher among statin-treated recipients compared with recipients not treated with statins (hazard ratio (HR) 2.26 (95% confidence interval (CI) 1.2-4.1), P = 0.008) ( Table 2 and Figure 1a ). Common Gramnegative pathogens were Pseudomonas aeruginosa, Escherichia coli and Acinetobacter baumannii. After adjustment for age, sex, disease risk, donor type, sex mismatch, stem cell source, conditioning regimen and CMV serostatus, statin treatment of recipients remained an independent predictor for the development of Gram-negative bacteremia (adjusted HR 2.22 (95% CI 1.2-4.2), P = 0.01). After additional adjustments for mucositis severity and gastrointestinal GVHD as time-dependent covariates, the results did not change (data not shown). Candidemia, invasive molds, CMV reactivation, CMV disease and respiratory viral infections ( Figure 1b) were detected at similar rates among recipients with and those without statin use ( Table 2 ).
Incidence of infections by HLA-matched sibling donor statin use The incidence of different infections by HLA-matched sibling donor statin use is shown in Table 3 . In univariate analysis, the risk of Gram-negative bacteremia was suggestively higher among recipients of grafts from statin-treated sibling donors compared with those given grafts from sibling donors who were not treated with statins (HR 1.97 (95% CI 1.0-4.0), P = 0.07) (Figure 1c) . A significantly higher incidence of respiratory viral infections was observed in recipients of grafts from statin-treated sibling donors (adjusted HR 2.84 (95% CI 1.3-6.0), P = 0.007) (Figure 1d ).
Association between statin use and infection severity and infection-related mortality We analyzed bacteremia-related mortality at day 30 after diagnosis. Among 94 HCT recipients who had Gram-negative bacteremia, 1 of 11 statin-treated recipients died of a bacteremia- Effect of statin use on infections according to GVHD prophylaxis In this study, GVHD prophylaxis was CYA based in 813 recipients and tacrolimus based in 411 recipients (Table 1) . In univariate and multivariate analyses, type of calcineurin inhibitor used was not associated with infection incidence and outcome. Therefore, type of calcineurin inhibitor used did not alter the conclusions of the present analysis (data not shown).
DISCUSSION
This study suggests that statin use in HCT recipients or donors was associated with an increased incidence in some pathogens. A higher incidence of Gram-negative bacteremia was observed with recipient statin use, whereas donor statin use appeared to increase the risk of recipient respiratory viral infections. However, bacteremia-related mortality and progression of respiratory virus upper tract infection to LRD in recipients were not affected by recipient or donor statin use. Considering that statin use was associated with a decreased GVHD risk 14, 15 and that GVHD and infections are strongly correlated, [17] [18] [19] [20] we expected to find decreased risks of infections associated with statin use. Our findings, however, were not in keeping with our expectation as donor and recipient statin use was associated with an increased incidence of Gram-negative bacteremia and respiratory viral infections, respectively. A recent report showed that older persons treated with statins had an increased risk of herpes zoster infections compared with those not treated with statins. 26 Statins have been shown to inhibit inflammatory chemokine expression, leukocyte migration and adhesion, proliferation of monocyte/macrophages and facilitate Th2 polarization and regulatory T-cell expansion.
1,2,27-29 In our study, patients were severely immunocompromised by the HCT procedure and ongoing treatment with immunosuppressive drugs. Therefore, further immunosuppression or immunomodulation by statins in recipients of hematopoietic allografts might have increased the incidence of some infections. As it is known that statins may alter metabolization rates of some antibiotics (that is, azole anti-fungals), 30, 31 indirect effects of statins on infectious outcomes cannot be excluded. However, most of the drug interactions relevant to the concurrent use of statins would be expected to increase rather than decrease exposures to antibiotics.
Although recipient statin use was associated with an increased incidence of Gram-negative bacteremia, donor statin use was associated with an increased incidence of respiratory viral infections. Furthermore, donor statin treatment has been associated with a reduced risk of severe acute GVHD. 15 Therefore, patients with statin-treated donors might have had fewer hospitalizations with an increased exposure to respiratory viruses in the outpatient setting. Conversely, through direct immunosuppressive effects, recipient statin treatment might have resulted in increased rates of Gram-negative bacteremias. Infection-related mortality and rates of progression to LRD associated with statin use, however, were lower than in the groups without statin use. This observation suggests that statin use in HCT recipients or donors is not associated with severe infection-related adverse outcomes. The latter finding was consistent with our previous report that showed no associations between recipient or donor statin use and overall or non-relapse mortality. 14 This study has several limitations. Despite the overall relatively large sample size (n = 1191), numbers of statin-treated recipients (n = 76) and donors (n = 85) were relatively small, which restricted our ability to reach definitive conclusions with respect to some infection rates and infection-related mortality. We were also unable to assess the impact of pharmakokinetic interactions between statins and antibiotics, and the possible impact of the combined use of statins in recipients and donor on posttransplant infections. Variations of statin type and treatment duration further limited our ability to perform subgroup analyses.
Although it can be assumed that donor and recipient statin use were surrogates of cardiovascular 'vulnerability' (primary or secondary statin prophylaxis in patients with hypercholesterolemia), our multivariate model included age and sex, the most important variables associated with cardiovascular risk. It is, therefore, less likely that associations between statin use and infections were driven by overall comorbidity differences between the statin-treated and statin-naive patient groups. Finally, we evaluated multiple different infections, which can produce positive results by chance. Hence, further studies aimed at confirming these findings and defining the underlying mechanisms are needed.
In conclusion, we found that recipient statin use was associated with a higher incidence of Gram-negative bacteremia and donor statin use was associated with a higher acquisition rate of respiratory viral infections. Infection-related mortality or progression to severe disease appeared to be comparable between 'statin use' and 'no statin use' groups. Thus, although some infections were more frequently observed in statin-treated donors or recipients, these infections were generally benign or responded well to treatment. Given the significant interest in statins for prevention and treatment of GVHD, these findings support the need for further large cohort studies to confirm our findings, and ultimately randomized trials to clarify the overall net benefit of statin use in this population.
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